Comment on FR Doc # 2012-30531

This is a Comment on the Drug Enforcement Administration (DEA) Proposed Rule: Schedules of Controlled Substances: Placement of Lorcaserin into Schedule IV

For related information, Open Docket Folder  Docket folder icon


Dear DEA

In reviewing the comments submitted please note that there is an interest by some hedge fund to disparage lorcaserin because they are facing a huge loss due to fighting against science and truth, and fortunately losing that fight when FDA approved the drug.

The hedge funds have been singing this mantra reflected in comment ID "DEA-2012-0007-0038" about a "drug that barely works".

According to the top obesity experts in this country such as Dr. Ed Hendricks on whom the FDA relied for advice, contend that the meaningful data for efficacy for lorcaserin are the following and not the data that hedge funds like to use!

Trials of Belviq on thousands of patients shows completers lost an average of 8% of body weight and responders lost between 11% and 12% of body weight in a year. The top 25% of weight losers lost an average of 35 pounds in one year. This is excellent efficacy no matter what hedge funds like to believe, given the medical community knows a modest 5% weight loss can have significant improvements on overall health.

Thank you for your wisdom and expediting this important medicine.
Comment Period Closed
Jan 18 2013, at 11:59 PM ET
ID: DEA-2012-0007-0039
Tracking Number: 1jx-831x-uxs2

Document Information

Date Posted: Jan 14, 2013
RIN: Not Assigned
Show More Details  

Submitter Information

Submitter Name: Reza Ganjavi